Abstract 1069
Background
Alectinib is a CNS penetrant and highly selective ALK inhibitor. The Japanese Risk Management Plan based on the phase I/II studies highlighted interstitial lung disease (ILD), liver function disorder, decreased neutrophil cell and white blood cell counts as identified risk in Japanese patients (pts). To investigate the safety and effectiveness of alectinib, including adverse drug reactions (ADR) of particular concern in the real world setting, a large scale surveillance funded by Chugai Pharmaceuticals has been implemented. This study is registered with the UMIN, number UMIN000014989.
Methods
From Sep 2014 to June 2015 all pts with ALK-positive recurrent/advanced NSCLC treated with alectinib, were enrolled in the study. The observation period was 18 months, ADR were collected. Overall survival (OS) was also assessed.
Results
By Jun 2015, a total of 1251 pts were registered. We analysed 1221 pts as the safety population. Baseline characteristics included: female (54% of population), median age (62 years), ECOG PS 3-4 (n = 89) (7%), pts who received first line (18%), second line (32%) or third line or more (50%) treatments, pts who received crizotinib (63%), brain metastases (41%). The overall incidence of ADRs was 53.6% (mostly grade 1/2), the most common were laboratory tests abnormality (27.7%). ILD events were reported in 47 pts (3.8% of population), including grade 3 events in 8 pts and grade 4 events in 1 pt, in which the rate of recovery or improvement was 92%. Events of liver function disorder were reported in 242 pts (19.8%), including grade 3 events in 24 pts, and events of neutrophil cell and white blood cell decrease were reported in 93 pts (7.6%), including grade 3 events in 12 pts and grade 4 events in 2 pts, in which the rates of recovery or improvement were 83% and 93%, respectively. Median OS was not reached. Overall survival rate at 12 months and 18 months were 82.4% and 76.2%, respectively.
Conclusions
These final data from this study in Japanese ALK-positive NSCLC pts provide an acceptable safety and effectiveness profile in the real-world setting. Alectinib was primarily one of the effective therapies for the treatment of ALK-positive NSCLC.
Clinical trial identification
Legal entity responsible for the study
Chugai Pharmaceutical CO., LTD.
Funding
Chugai Pharmaceutical CO., LTD.
Editorial Acknowledgement
Disclosure
Y. Ohe: Consuting or advisory role, honoraria: Chugai Pharm Co., Ltd.; Research funding to institution: Chugai Pharm Co., Ltd. N. Yamamoto: Consuting or advisory role, speakers' bureau, honoraria: Chugai Pharm Co., Ltd. Research funding to instution: Chugai Pharm Co., Ltd. A. Gemma, M. Kusumoto, N. Masuda: Consuting or advisory role: Chugai Pharm CO., LTD. I. Yamada, T. Ishii: Employment: Chugai Pharm Co., Ltd.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract